Hepatitis 15 virus （HBV） IS an admitted oncogenic virus. Many epidemiological and molecularbiological studies have demonstrated that chronic infection with HBV is a major risk factor associated with the development ...Hepatitis 15 virus （HBV） IS an admitted oncogenic virus. Many epidemiological and molecularbiological studies have demonstrated that chronic infection with HBV is a major risk factor associated with the development of hepatocellular carcinoma （HCC） and intrahepatic bile duct cancer. Compared with hepatocytes and intrahepatic bile duct epithelial cells, extrahepatic bile duct epithelial cells have autoploid in embryogenesis, continuity in anatomy and a similar internal environment. The question arises whether extrahepatic bile duct epithelial cells can receive HBV infection or not？ The role of hepatitis viral infection in the pathogenesis of bile duct carcinoma has not yet been clarified, although a causative relationship between HBV or HCV infection and extrahepatic bile duct carcinoma has been reported in the literature. In this study, we focused on the evidence of hepatitis viral infection in tissue of bile duct carcinoma.展开更多
Fibrolamellar carcinoma(FLC)is a rare variant of hepatocellular carcinoma(HCC),comprising 1%–9%of all HCCs.FLC is a poorly understood malignancy,which seems to be more prevalent in young patients with no underlying l...Fibrolamellar carcinoma(FLC)is a rare variant of hepatocellular carcinoma(HCC),comprising 1%–9%of all HCCs.FLC is a poorly understood malignancy,which seems to be more prevalent in young patients with no underlying liver diseases.The term“fibrolamellar”is derived from thick fibrous collagen bands surrounding the tumor cells.Unlike HCC,cirrhosis and viral hepatitis infection are not predisposing to FLC,and it is not associated with elevations in serum alpha-fetoprotein.FLC patients often present with vague abdominal pain,nausea,malaise,and weight loss.Most cases present are at an advanced stage at the time of initial diagnosis.However,curative treatment options can still be offered to up to 70%of patients.Surgery(resection/liver transplantation)is the mainstay of treatment and the only potentially curative option.FLCs have been less chemoresponsive than the conventional HCC,however,in advanced cases,multimodality treatments can be effective.Recent advances in molecular studies of FLC have found a unique DNAJB1–PRKACA fusion transcript in most of the cases studied.The review aims to describe clinical characteristics,diagnostic methods,and therapeutic modalities for this rare tumor to raise awareness among clinicians and surgeons.展开更多
文摘Hepatitis 15 virus （HBV） IS an admitted oncogenic virus. Many epidemiological and molecularbiological studies have demonstrated that chronic infection with HBV is a major risk factor associated with the development of hepatocellular carcinoma （HCC） and intrahepatic bile duct cancer. Compared with hepatocytes and intrahepatic bile duct epithelial cells, extrahepatic bile duct epithelial cells have autoploid in embryogenesis, continuity in anatomy and a similar internal environment. The question arises whether extrahepatic bile duct epithelial cells can receive HBV infection or not？ The role of hepatitis viral infection in the pathogenesis of bile duct carcinoma has not yet been clarified, although a causative relationship between HBV or HCV infection and extrahepatic bile duct carcinoma has been reported in the literature. In this study, we focused on the evidence of hepatitis viral infection in tissue of bile duct carcinoma.
文摘Fibrolamellar carcinoma(FLC)is a rare variant of hepatocellular carcinoma(HCC),comprising 1%–9%of all HCCs.FLC is a poorly understood malignancy,which seems to be more prevalent in young patients with no underlying liver diseases.The term“fibrolamellar”is derived from thick fibrous collagen bands surrounding the tumor cells.Unlike HCC,cirrhosis and viral hepatitis infection are not predisposing to FLC,and it is not associated with elevations in serum alpha-fetoprotein.FLC patients often present with vague abdominal pain,nausea,malaise,and weight loss.Most cases present are at an advanced stage at the time of initial diagnosis.However,curative treatment options can still be offered to up to 70%of patients.Surgery(resection/liver transplantation)is the mainstay of treatment and the only potentially curative option.FLCs have been less chemoresponsive than the conventional HCC,however,in advanced cases,multimodality treatments can be effective.Recent advances in molecular studies of FLC have found a unique DNAJB1–PRKACA fusion transcript in most of the cases studied.The review aims to describe clinical characteristics,diagnostic methods,and therapeutic modalities for this rare tumor to raise awareness among clinicians and surgeons.
